VC
CLDX icon

Vivo Capital’s Celldex Therapeutics CLDX Stock Holding History

Vivo Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-198,983
Closed -$5.59M – 50
2022
Q3 		$5.59M Sell
198,983
-359,653
-64% -$11M 0.62% 37
2022
Q2 		$15.1M Sell
558,636
-69,720
-11% -$2.02M 1.51% 15
2022
Q1 		$21.4M Buy
628,356
+143,903
+30% +$4.6M 1.47% 14
2021
Q4 		$18.7M Hold
484,453
– – 1.13% 23
2021
Q3 		$26.2M Sell
484,453
-484,453
-50% -$22.7M 1.17% 21
2021
Q2 		$32.4M Sell
968,906
-322,969
-25% -$8.87M 1.4% 20
2021
Q1 		$26.6M Hold
1,291,875
– – 0.94% 22
2020
Q4 		$22.6M Sell
1,291,875
-430,625
-25% -$7.75M 1.01% 22
2020
Q3 		$25.5M Buy
1,722,500
+122,500
+8% +$1.44M 1.48% 16
2020
Q2 		$20.8M Buy
+1,600,000
New +$7.09M 1.49% 17

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vivo Capital's CLDX Position: Q4 2022 in Review

Vivo Capital sold out of Celldex Therapeutics (CLDX) in Q4 2022, closing a stake of 198,983 shares — an estimated $5.59M sold.

Vivo Capital first reported a position in CLDX in Q2 2020 and held it in 10 quarters. The position peaked at $32.4M in Q2 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • Vivo Capital reported no remaining Celldex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Vivo Capital sold 198,983 Celldex Therapeutics shares in Q4 2022, an estimated $5.59M.
  • Vivo Capital first reported a position in Celldex Therapeutics in Q2 2020 and held it in 10 quarters.
  • Vivo Capital's Celldex Therapeutics position peaked at $32.4M in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.